p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies
Status:
Completed
Trial end date:
2018-01-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how well the study drug works and safety of oral
decitabine in patients with refractory or relapsed lymphoid malignancies. The decitabine is
being given at a lower dose than used for its approved use. It is also being given with
another drug, tetrahydrouridine (THU), to improve the exposure of lymphoma cells to
decitabine.